DeepHealth has won FDA clearance for two new Breast Suite features: an AI tool that flags cardiovascular risk from routine screening mammograms with over 90% sensitivity, and an upgraded Mammo Dx that compares current and prior exams to cut unnecessary recalls.
Medtronic has won FDA clearance for Stealth AXiS, a platform that combines AI-based surgical planning, real-time navigation and robotics for spine surgery, with a follow-on clearance expanding it into cranial and ENT procedures.
Meta has begun production of its custom Iris AI chip, built with Broadcom on TSMC's 3-nanometer process, as part of a plan to double its AI computing capacity to 14 gigawatts by 2027 and reduce its reliance on Nvidia GPUs for internal workloads.
Subtle Medical won FDA clearance to bring its AI image-enhancement software to CT scans after years of use on MRI, a move that could let hospitals lower radiation doses while preserving diagnostic image quality across tens of millions of annual CT exams.
Qualified Health raised a $125 million Series B on March 26, 2026 led by New Enterprise Associates to expand its enterprise AI governance platform, which the company says now supports 400,000 users across health systems representing about 5% of U.S. hospital revenue.
AbbVie and Iambic Therapeutics announced a multi-year AI drug discovery collaboration on September 21, 2026 targeting small-molecule therapies in immunology, neuroscience and oncology, part of a wider wave of pharma-AI deals that also saw Novo Nordisk partner with Anthropic the same week.
Pearl became the first dental AI company cleared by the FDA for both 2D and 3D imaging as of December 2025, with the company citing clinical data showing diagnostic accuracy rising from 82% to 98% when dentists use its Second Opinion software.
Washington state authorized statewide Medicaid reimbursement for Intuition Robotics' ElliQ companion device on March 18, 2026, the first time any U.S. state has fully covered a social AI robot as a 'Smart Care Device' for home-based long-term care recipients.
Eli Lilly signed a deal worth up to $2.75 billion with Insilico Medicine in March 2026 for a portfolio of preclinical, AI-designed drug candidates, one of the largest AI-pharma partnerships to date, with only $115 million guaranteed upfront.
Hyodol, a ChatGPT-powered companion doll already used by roughly 12,000 elderly South Koreans living alone, registered with the FDA in late 2024 and is targeting a full US launch in 2026 to combat senior isolation and detect falls.